United States - English - NLM (National Library of Medicine)

glenmark pharmaceuticals inc., usa - moexipril hydrochloride (unii: q1umg3uh45) (moexiprilat - unii:h3753190js) - moexipril hydrochloride 7.5 mg - moexipril hydrochloride tablets are indicated for treatment of patients with hypertension. they may be used alone or in combination with thiazide diuretics. in using moexipril hydrochloride tablets, consideration should be given to the fact that another ace inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. available data are insufficient to show that moexipril hydrochloride tablets do not have a similar risk (see warnings ). in considering use of moexipril hydrochloride tablets, it should be noted that in controlled trials ace inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. in addition, ace inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see warnings, angioedema ). moexipril hydrochloride is contraindicated in patients who are hypersensitive to this product and in patients with a history of angioedema related to previous treatment with an ace inhibitor. do not co-administer aliskiren with moexipril hydrochloride in patients with diabetes (see precautions, drug interactions).

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - moexipril hydrochloride (unii: q1umg3uh45) (moexiprilat - unii:h3753190js) - moexipril hydrochloride 7.5 mg - moexipril hydrochloride tablets usp are indicated for treatment of patients with hypertension. it may be used alone or in combination with thiazide diuretics. in using moexipril hydrochloride tablets usp, consideration should be given to the fact that another ace inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. available data are insufficient to show that moexipril hydrochloride tablets usp do not have a similar risk (see warnings ). in considering use of moexipril hydrochloride tablets usp, it should be noted that in controlled trials ace inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. in addition, ace inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see warnings, angioedema ). moexipril hydrochloride tablets are contraindicated in patients who are hypersensitive to this product and in patients with a history of a

United States - English - NLM (National Library of Medicine)

carilion materials management - moexipril hydrochloride (unii: q1umg3uh45) (moexiprilat - unii:h3753190js) - moexipril hydrochloride 7.5 mg - moexipril hydrochloride tablets usp are indicated for treatment of patients with hypertension. it may be used alone or in combination with thiazide diuretics. in using moexipril hydrochloride tablets usp, consideration should be given to the fact that another ace inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. available data are insufficient to show that moexipril hydrochloride tablets usp do not have a similar risk (see warnings ). in considering use of moexipril hydrochloride tablets usp, it should be noted that in controlled trials ace inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. in addition, ace inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see warnings, angioedema ). moexipril hydrochloride tablets are contraindicated in patients who are hypersensitive to this product and in patients with a history of a

United States - English - NLM (National Library of Medicine)

glenmark pharmaceuticals inc., usa - moexipril hydrochloride (unii: q1umg3uh45) (moexiprilat - unii:h3753190js), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - moexipril hydrochloride 7.5 mg - moexipril hydrochloride and hydrochlorothiazide tablets are indicated for treatment of patients with hypertension. this fixed combination is not indicated for the initial therapy of hypertension (see dosage and administration). in using moexipril hydrochloride and hydrochlorothiazide tablets, consideration should be given to the fact that another ace inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. available data are insufficient to show that moexipril hydrochloride and hydrochlorothiazide tablets do not have a similar risk (see warnings, neutropenia/agranulocytosis ). in addition, ace inhibitors, for which adequate data are available, cause a higher rate of angioedema in black than in nonblack patients (see warnings, angioedema ). moexipril hydrochloride and hydrochlorothiazide tablets are contraindicated in patients who are hypersensitive to any component of this product and in patients with a history of angioedema related to prev

United States - English - NLM (National Library of Medicine)

heritage pharmaceuticals inc. - moexipril hydrochloride (unii: q1umg3uh45) (moexiprilat - unii:h3753190js), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - moexipril hydrochloride 7.5 mg - moexipril hydrochloride and hydrochlorothiazide tablets are indicated for treatment of patients with hypertension. this fixed combination is not indicated for the initial therapy of hypertension ( see dosage and administration). in using moexipril hydrochloride and hydrochlorothiazide tablets, consideration should be given to the fact that another ace inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. available data are insufficient to show that moexipril hydrochloride and hydrochlorothiazide tablets does not have a similar risk (see warnings, neutropenia/agranulocytosis ). in addition, ace inhibitors, for which adequate data are available, cause a higher rate of angioedema in black than in nonblack patients (see warnings, angioedema ). moexipril hydrochloride and hydrochlorothiazide tablets are contraindicated in patients who are hypersensitive to any component of this product and in patients with a history of angioedema related

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - moexipril hydrochloride (unii: q1umg3uh45) (moexiprilat - unii:h3753190js), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - moexipril hydrochloride 7.5 mg - moexipril hydrochloride and hydrochlorothiazide tablets usp are indicated for treatment of patients with hypertension. this fixed combination is not indicated for the initial therapy of hypertension (see dosage and administration). in using moexipril hydrochloride and hydrochlorothiazide tablets usp, consideration should be given to the fact that another ace inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. available data are insufficient to show that moexipril hydrochloride and hydrochlorothiazide tablets usp do not have a similar risk (see warnings , neutropenia/agranulocytosis ). in addition, ace inhibitors, for which adequate data are available, cause a higher rate of angioedema in black than in nonblack patients (see warnings , angioedema ). moexipril hydrochloride and hydrochlorothiazide tablets are contraindicated in patients who are hypersensitive to any component of this product and in patients with a history of angioedema r

Ireland - English - HPRA (Health Products Regulatory Authority)

chanelle pharmaceuticals manufacturing limited - benazepril hydrochloride - film-coated tablet - 2.5 mg/tablet - benazepril - dogs - cardiovascular

Ireland - English - HPRA (Health Products Regulatory Authority)

chanelle pharmaceuticals manufacturing limited - benazepril hydrochloride - film-coated tablet - 20 mg/tablet - benazepril - dogs - cardiovascular

United States - English - NLM (National Library of Medicine)

avera mckennan hospital - moexipril hydrochloride (unii: q1umg3uh45) (moexiprilat - unii:h3753190js) - moexipril hydrochloride 7.5 mg

United States - English - NLM (National Library of Medicine)

avkare, inc. - moexipril hydrochloride (unii: q1umg3uh45) (moexiprilat - unii:h3753190js), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - moexipril hydrochloride 7.5 mg - moexipril hydrochloride and hydrochlorothiazide tablets usp are indicated for treatment of patients with hypertension. this fixed combination is not indicated for the initial therapy of hypertension (see dosage and administration). in using moexipril hydrochloride and hydrochlorothiazide tablets usp, consideration should be given to the fact that another ace inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. available data are insufficient to show that moexipril hydrochloride and hydrochlorothiazide tablets usp do not have a similar risk (see warnings , neutropenia/agranulocytosis ). in addition, ace inhibitors, for which adequate data are available, cause a higher rate of angioedema in black than in nonblack patients (see warnings , angioedema ). moexipril hydrochloride and hydrochlorothiazide tablets are contraindicated in patients who are hypersensitiv